Tech Company Financing Transactions
Atavistik Bio Funding Round
Atavistik Bio, operating out of Cambridge, received $60 million from The Column Group, Lux Capital and Nextech Invest.
Transaction Overview
Company Name
Announced On
8/25/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for the development of its drug discovery platform, and future identification of select drug candidates based on deep knowledge of disease relevant pathways that have evolved over millions of years by nature to be allosterically regulated by metabolites.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Atavistik Bio's high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature's own mechanisms of allosteric control.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Josey
Founder
Ralph DeBerardinis
Founder
Jared Rutter
President
Marion Dorsch
Browse more venture capital transactions:
Prev: 8/25/2021: Hunters venture capital transaction
Next: 8/25/2021: Checkpoint Surgical venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs